EPO

Evidence in perspective

The named U.S. product label is the appropriate source for its approved use, contraindications and handling. EPOGEN epoetin alfa: IV elimination half-life was 4–13 hours in adults and children with chronic kidney disease. In the cited subcutaneous regimens in anemic cancer patients, mean half-life was about 40 hours (range 16–67). Route, population and regimen differ; the 5–24-hour subcutaneous time to peak is not half-life. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.

Who was studied

The population specified by this product label; other indications and jurisdictions remain outside this check.

What the sources found

Treatment of specified anemias and reduction of transfusion needs in selected surgical patients.

Regulatory scope

U.S. label record for BLA103234. This does not confer authorization on other products using the ingredient name.

What remains unknown

Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.

How it works

EPOGEN epoetin alfa injection

Consult the product label for pharmacology. A mechanism does not extend its approved indications.

Approved product exists

Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.

Understanding the evidence

Reported adverse effects

• Boxed warning includes death, stroke, heart attack, thrombosis and tumor progression or recurrence.

Named U.S. presentation only; selected label sections.

Source · Warnings and precautions / boxed warning